Diya Lahiri, pharmaceutical industry analyst, said: "The world market for monoclonal antibody treatments will benefit from the entry of new products this decade. There is much scope for therapies that offer improved administration methods, efficacy and tolerability, especially in the autoimmune disorders sector of the market."
This new study predicts how treatments such as Avastin, Herceptin, MabThera, Remicade, Humira, Tysabri and Lucentis will perform to 2021. It shows commercial prospects for Roche, J&J, Abbott, Biogen Idec, Novartis and other companies. Markets and R&D pipelines for mAb-based treatments remain strong.
Products emerging from the R&D pipeline will help the monoclonal antibody treatments industry and market to grow this decade, the report explains. Also, the approval of existing products for new indications will expand the mAbs market and benefit patients. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry areas.
To see sample pages of the report please visit http://www.visiongain.com/
For an exec summary please email Sara Peerun on:
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@
# # #
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.